• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Weave Completes TrueLark Acquisition

    5/19/25 10:00:00 PM ET
    $WEAV
    Computer Software: Prepackaged Software
    Technology
    Get the next $WEAV alert in real time by email

    Files S-3 Registration Statement for Equity Issuance

    Weave (NYSE:WEAV), a leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses, today announced the successful closing of its previously announced acquisition of TrueLark. Truelark is an AI-powered receptionist and front-desk automation platform. The transaction marks a significant milestone in Weave's strategy to lead the next evolution of AI in healthcare communications.

    Additionally, on May 16, 2025, Weave filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission to facilitate the registration for resale of the shares issued in the TrueLark transaction, as required by the merger agreement. Weave has no current plans to offer or sell any additional securities to the public under this shelf registration.

    For more details and the previous announcement from this transaction, please see the following link: Weave Communications to Acquire TrueLark, Accelerating AI-Powered Front Office Automation.

    About Weave

    Weave is a leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire patient journey. Weave's software solutions transform how healthcare practices attract, communicate with, and engage patients and clients to grow their business. Weave seamlessly integrates billing and payment requests into communication workflows, streamlining payment timelines, reducing accounts receivable, and supporting practice profitability. In the past year, Weave has been named an Inc. Power Partner, a G2 leader in Patient Relationship Management software and a Top 50 Product for Small Business. To learn more, visit getweave.com/newsroom/.

    About TrueLark

    TrueLark is an AI-powered virtual receptionist for appointment-based small and medium-sized businesses. Its agentic AI platform handles scheduling, rescheduling, and inquiries via SMS and web chat—delivering 24/7 patient and client support. TrueLark helps customers follow up on missed calls, increase bookings, and improve operational efficiency. To learn more, visit truelark.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250519093381/en/

    Media Contact:

    Natalie House

    Sr. Director of Content and Communications, Weave

    [email protected]

    Investor Contact:

    Mark McReynolds

    Head of Investor Relations, Weave

    [email protected]

    Get the next $WEAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WEAV

    DatePrice TargetRatingAnalyst
    2/26/2024$15.00Outperform → Strong Buy
    Raymond James
    1/2/2024$8.00 → $15.00Neutral → Overweight
    Piper Sandler
    6/26/2023$5.00 → $13.00Hold → Buy
    Loop Capital
    5/4/2023$6.00Mkt Perform → Outperform
    Raymond James
    8/4/2022$12.00 → $5.00Buy → Hold
    Loop Capital
    3/9/2022$37.00 → $13.00Buy → Neutral
    Goldman Sachs
    3/3/2022$22.00 → $11.00Buy
    Guggenheim
    3/3/2022$12.00 → $10.00Neutral
    Citigroup
    More analyst ratings